Poseida Therapeutics, Inc.

NasdaqGS:PSTX Stock Report

Market Cap: US$280.8m

Poseida Therapeutics Balance Sheet Health

Financial Health criteria checks 6/6

Poseida Therapeutics has a total shareholder equity of $103.7M and total debt of $58.6M, which brings its debt-to-equity ratio to 56.5%. Its total assets and total liabilities are $273.9M and $170.2M respectively.

Key information

56.5%

Debt to equity ratio

US$58.59m

Debt

Interest coverage ration/a
CashUS$212.20m
EquityUS$103.70m
Total liabilitiesUS$170.18m
Total assetsUS$273.89m

Recent financial health updates

Recent updates

Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 27%

Apr 09
Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 27%

Poseida: April 2024 Data Could Shed Light On Differentiated CAR-T Advancement

Mar 17

Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?

Jan 24
Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?

Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Price Boosted 43% But Its Business Prospects Need A Lift Too

Dec 18
Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Price Boosted 43% But Its Business Prospects Need A Lift Too

New Forecasts: Here's What Analysts Think The Future Holds For Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Aug 13
New Forecasts: Here's What Analysts Think The Future Holds For Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Little Excitement Around Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Revenues As Shares Take 44% Pounding

Apr 17
Little Excitement Around Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Revenues As Shares Take 44% Pounding

Poseida Therapeutics: Collaboration Agreement With Roche Helps Validate Genetic Engineering Tech

Sep 04

Poseida Therapeutics GAAP EPS of -$0.69 beats by $0.08, revenue of $2.7M beats by $1.77M

Aug 11

Poseida jumps 56% as Roche eyes CAR-T drugs in deal worth up to $6B

Aug 03

Earnings Release: Here's Why Analysts Cut Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) Price Target To US$16.25

May 15
Earnings Release: Here's Why Analysts Cut Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) Price Target To US$16.25

Poseida Therapeutics: Genome Engineering For Safer Cell Therapies

Oct 30

What Type Of Shareholders Make Up Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Registry?

Mar 19
What Type Of Shareholders Make Up Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Registry?

Did Poseida Therapeutics, Inc. (NASDAQ:PSTX) Insiders Buy Up More Shares?

Jan 25
Did Poseida Therapeutics, Inc. (NASDAQ:PSTX) Insiders Buy Up More Shares?

Poseida Therapeutics (PSTX) Presents At 62nd Virtual Annual Meeting of ASH - Slideshow

Dec 09

FDA lifts clinical hold on Poseida's prostate cancer cell therapy study

Nov 02

Financial Position Analysis

Short Term Liabilities: PSTX's short term assets ($226.5M) exceed its short term liabilities ($71.3M).

Long Term Liabilities: PSTX's short term assets ($226.5M) exceed its long term liabilities ($98.9M).


Debt to Equity History and Analysis

Debt Level: PSTX has more cash than its total debt.

Reducing Debt: PSTX had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PSTX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: PSTX has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 2.1% each year.


Discover healthy companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.